摘要:
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
摘要:
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
摘要:
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.
摘要:
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.
摘要:
A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Y51, Q55, Q56, N66, M83, V90, M93, or F94 in SEQ ID NO:1; or at least one mutation at Q3, F7 A13, L27, W42, G44, Y50, Q54, N65, N67, M82, V89, M92, or F93 in SEQ ID NO:2, or a deletion at the terminal end of less than 20 amino acids. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, AI4R, L28A, L29S, W43R, G45T, Q55I, Q56A, N66I, N67A, M83I, V90R, M93T, or F94Q in SEQ ID NO:1, and Q3L, F7I, A13R, L27A, L28S, W42R, Q44T, Q54I, N65I, M82I, V89R, M92T, and F93Q in SEQ ID NO:2. Similarly, the genetically modified strain may also secrete ESAT-6 with a hexa-histidine tag, tetra-cysteine tag, or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译:提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株,其中所述遗传修饰菌株包含至少一个包含SEQ ID NO:1,SEQ ID NO:2或两者的经修饰的序列,或在T2处具有至少一个突变, SEQ ID NO:1中的Q4,F8,A14,L28,L29,W43,G45,Y51,Q55,Q56,N66,M83,V90,M93或F94; 或SEQ ID NO:2中的Q3,F7A13,L27,W42,G44,Y50,Q54,N65,N67,M82,V89,M92或F93的至少一个突变,或末端的缺失小于 20个氨基酸。 在优选实施方案中,突变是SEQ ID NO:1中的T2H,Q4L,F8I,AI4R,L28A,L29S,W43R,G45T,Q55I,Q56A,N66I,N67A,M83I,V90R,M93T或F94Q中的至少一种 ,以及SEQ ID NO:2中的Q3L,F7I,A13R,L27A,L28S,W42R,Q44T,Q54I,N65I,M82I,V89R,M92T和F93Q。 类似地,遗传修饰的菌株也可以分泌具有六组氨酸标签,四半胱氨酸标签或FLAG标签的ESAT-6,GFP-融合物或C末端的短截短小于20个氨基酸 。
摘要:
A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Q55, Q56, N66, M83, V90, M93, or F94. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, A14R, L28A, L29S, W43R, G45T, Y51, Q55I, Q56A, N66I, N66A, M83I, V90R, M93T, or F94Q. Similarly, the genetically modified strain may also secrete ESAT-6 with a a histidine tag, tetra-cysteine tag or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译:提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株,其中所述遗传修饰菌株包含至少一个包含SEQ ID NO:1,SEQ ID NO:2或两者的经修饰的序列,或在T2处具有至少一个突变, Q4,F8,A14,L28,L29,W43,G45,Q55,Q56,N66,M83,V90,M93或F94。 在优选的实施方案中,突变是T2H,Q4L,F8I,A14R,L28A,L29S,W43R,G45T,Y51,Q55I,Q56A,N66I,N66A,M83I,V90R,M93T或F94Q中的至少一种。 类似地,遗传修饰的菌株也可以在小于20个氨基酸的C末端分泌具有组氨酸标签,四半胱氨酸标签或FLAG标签,GFP融合物或短截短的ESAT-6。
摘要:
The present invention is the identification of a nucleotide sequence which make it possible in particular to distinguish an infection resulting from the vast majority of Mycobacterium tuberculosis strains from an infection resulting from Mycobacterium africanum, Mycobacterium canetti, Mycobacterium microti, Mycobacterium bovis, Mycobacterium bovis BCG. The subject of the present invention is also a method for detecting the sequences in question by the products of expression of these sequences and the kits for carrying out these methods. Finally, the subject of the present invention is novel vaccines.
摘要:
The present invention is the identification of a nucleotide sequence which make it possible in particular to distinguish an infection resulting from the vast majority of Mycobacterium tuberculosis strains from an infection resulting from Mycobacterium africanum, Mycobacterium canetti, Mycobacterium microti, Mycobacterium bovis, Mycobacterium bovis BCG. The subject of the present invention is also a method for detecting the sequences in question by the products of expression of these sequences and the kits for carrying out these methods. Finally, the subject of the present invention is novel vaccines.